



Synergy between Pharmacy and Biotechnology in the Development of Precision Therapies to Enhance the Quality of Healthcare Services

Rifa Andriana¹ , Aiman Fariq² , Nina Anis³

¹ Universitas Islam Negeri Mahmud Yunus Batusangkar, Indonesia

² UCSI University, Malaysia

³ Monash University, Malaysia

ABSTRACT

Background. The increasing variability of patient responses to pharmacological treatments has encouraged a transition from conventional therapeutic approaches toward precision medicine. This transformation requires strong collaboration between pharmaceutical sciences and biotechnology to develop therapies that are more targeted, safe, and effective.

Purpose. This study aimed to analyze the synergistic role of pharmacy and biotechnology in the development of precision therapy and to evaluate its contribution to improving the quality of healthcare services.

Method. This research employed a qualitative literature review approach by examining scientific articles, review studies, and healthcare policy reports published between 2015 and 2025. Data were collected from reputable international databases and analyzed using a descriptive-analytical method to identify key trends, innovations, and implications of biotechnology integration in pharmacy practice.

Results. The findings revealed that biotechnological advancements, including pharmacogenomics, monoclonal antibody development, and molecular diagnostic technologies, provide essential support for pharmacists in designing individualized treatment strategies. The integration of these innovations improves therapeutic accuracy, reduces adverse drug reactions, enhances medication safety, and promotes more efficient healthcare delivery.

Conclusion. The synergy between pharmacy and biotechnology represents a critical foundation for advancing precision therapy. This interdisciplinary integration strengthens patient-centered healthcare systems by enabling personalized treatment approaches that are more effective, sustainable, and responsive to individual patient needs.

KEYWORDS

Biotechnology , Pharmacy, Precision Therapy

Citation: Andriana, R., Fariq, A., & Anis, N. (2026) Synergy between Pharmacy and Biotechnology in the Development of Precision Therapies to Enhance the Quality of Healthcare Service. *Journal of Advanced Pharmaceutical Research Sciences and Sustainability (JAPRSS)*, 2(1), 59–67.

<https://doi.org/10.70177/japrss.v2i1.2919>

Correspondence:

Mahyudin Ritonga,
mahyudinritonga@gmail.com

Received: October 12, 2025

Accepted: Januari 15, 2026

Published: March 22, 2026

INTRODUCTION

The rapid advancement of biomedical science has significantly transformed healthcare delivery systems worldwide (Leelakrishna Reddy, 2023). One of the most notable transformations is the emergence of precision therapy, which emphasizes individualized treatment based on genetic, molecular, and clinical characteristics of patients. Conventional therapeutic models that apply uniform treatment regimens are increasingly considered inadequate due to variations in drug response and disease



progression among individuals (Maesaroh, 2025). Pharmaceutical science plays a crucial role in ensuring. At the same time, biotechnology contributes advanced tools and platforms, including genetic engineering, biomarker identification, and molecular diagnostics, which enable targeted drug development (Williams, 2023). Previous studies have demonstrated that integrating pharmacogenomics into clinical practice can significantly reduce adverse drug reactions and improve therapeutic outcomes.

Despite these advancements, the implementation of precision therapy remains fragmented, particularly in developing healthcare systems. Limited interdisciplinary collaboration and insufficient integration between pharmacy practice and biotechnology research represent critical gaps. Therefore, this article addresses the importance of strengthening synergy between pharmacy and biotechnology as a strategic approach to enhancing healthcare quality. The novelty of this study lies in its integrative perspective that positions pharmacists not merely as medication providers but as key actors in biotechnology-driven precision healthcare.

The role of pharmacogenomics, a critical branch of precision therapy, cannot be overstated in the context of modern medicine. By identifying genetic variations that affect individual responses to drugs, pharmacogenomics enables more accurate predictions of drug efficacy and safety. This individualized approach helps to optimize treatment plans by tailoring drug choices and dosages to each patient's unique genetic makeup, reducing the risk of adverse drug reactions. As the field of pharmacogenomics continues to evolve, there is growing potential to improve therapeutic outcomes, particularly for patients with complex conditions like cancer, cardiovascular diseases, and neurological disorders. Moreover, the widespread adoption of pharmacogenomic testing could also lead to a reduction in healthcare costs by preventing ineffective treatments and minimizing the need for trial-and-error approaches in prescribing medications.

In parallel with pharmacogenomics, the integration of biotechnology in drug discovery and development offers new opportunities to address unmet medical needs. Innovations such as monoclonal antibodies, gene therapies, and CAR T-cell therapies have revolutionized the treatment of previously intractable diseases. These biotechnological advancements have shown remarkable success in treating cancers, autoimmune disorders, and genetic diseases by targeting the root causes of these conditions. However, the full potential of biotechnology in precision medicine cannot be realized without effective collaboration between biotechnologists and pharmacists, who must work together to ensure that these novel therapies are accessible, affordable, and safe for patients.

The increasing complexity of drug therapies and the growing availability of biotechnological treatments have led to a significant shift in the responsibilities of pharmacists. Traditionally viewed as medication dispensers, pharmacists are now positioned as integral members of healthcare teams, with an essential role in optimizing therapy through medication management, patient counseling, and ensuring safe drug use. In the context of precision therapy, pharmacists' expertise in drug interactions, pharmacokinetics, and pharmacodynamics is invaluable in maximizing therapeutic outcomes while minimizing potential risks. Thus, enhancing collaboration between pharmacists and biotechnologists is vital for realizing the full benefits of precision medicine.

Despite the clear advantages of this integrated approach, several challenges remain. The implementation of precision therapy on a global scale, particularly in low- and middle-income countries, is hindered by limited access to advanced biotechnology, a lack of trained professionals, and financial constraints. Furthermore, the regulatory landscape for precision medicine is still evolving, with many countries lacking comprehensive frameworks to govern the use of genomic data in clinical settings. Overcoming these barriers will require concerted efforts from governments,

healthcare providers, and industry stakeholders to create a supportive environment for the widespread adoption of precision therapies.

In addition to these practical challenges, ethical concerns surrounding the use of genomic information in healthcare must also be addressed. The use of genetic data raises questions about privacy, data security, and the potential for discrimination based on genetic predispositions. Ensuring that patients' genetic information is handled responsibly and that they are fully informed about the potential benefits and risks of precision therapy is essential for building trust in this transformative field. The integration of ethics into the curriculum of pharmacy and biotechnology programs will help prepare future professionals to navigate these challenges and make informed decisions about the use of genetic and molecular information in healthcare.

One promising avenue for enhancing interdisciplinary collaboration between pharmacy and biotechnology is the development of joint educational programs and research initiatives. By fostering greater understanding and knowledge exchange between the two fields, these initiatives can cultivate a workforce that is better equipped to tackle the complexities of precision medicine. Universities and research institutions should prioritize the creation of interdisciplinary training programs that combine pharmacology, biotechnology, bioinformatics, and clinical practice. This will enable future professionals to work collaboratively across disciplines and contribute to the development of more effective, personalized treatment strategies.

Another key aspect of advancing precision therapy is the need for robust data infrastructure. The successful implementation of precision medicine relies on the collection, storage, and analysis of vast amounts of patient data, including genomic, clinical, and environmental information. To support this, healthcare systems must invest in electronic health records (EHR) and other data management technologies that allow for seamless integration and sharing of patient data across different healthcare providers. This infrastructure will facilitate the development of predictive models that can guide therapeutic decisions and enable more personalized care.

Ultimately, the integration of pharmacy and biotechnology is not just a matter of improving drug efficacy but also about enhancing the overall healthcare experience for patients. By leveraging the strengths of both fields, healthcare systems can provide more holistic care that addresses the unique needs of each individual. Pharmacists, in particular, are well-positioned to bridge the gap between cutting-edge biotechnological innovations and patient care, ensuring that new therapies are appropriately integrated into clinical practice. With continued investment in research, education, and infrastructure, the future of precision therapy looks promising, offering the potential for safer, more effective treatments that improve health outcomes on a global scale.

RESEARCH METHODOLOGY

This study utilized a literature review approach to examine the development and application of precision therapy through pharmacy biotechnology integration. The population of data consisted of peer-reviewed journal articles, systematic reviews, and institutional reports related to pharmaceutical biotechnology and healthcare innovation. The sampling technique employed purposive sampling with inclusion criteria focusing on publications between 2015 and 2025.

Data collection involved systematic searching of scientific databases using relevant keywords. The analysis plan applied descriptive and comparative analysis to identify patterns, innovations, and challenges. Validity was ensured through source triangulation, while reliability was strengthened by cross-referencing findings from multiple high-impact journals. This methodological approach allows replication and provides a comprehensive overview of the current state of knowledge (Snyder, 2019).

RESULT AND DISCUSSION

The results reveal that biotechnology-based pharmaceutical products, including biologics, biosimilars, and gene-based therapies, have expanded the scope of precision therapy. Pharmacogenomic testing enables pharmacists to predict patient-specific drug metabolism, thereby optimizing dosage and reducing therapeutic failure. This aligns with global trends emphasizing individualized therapeutic decision-making supported by molecular-level evidence. Furthermore, the collaboration between pharmacists and biotechnologists facilitates evidence-based clinical decision-making across the drug development and clinical implementation continuum. Pharmacists play a central role in translating complex biotechnological data such as genomic profiles and biomarker results into clinically actionable therapeutic recommendations.

Table 1. Synergy between Pharmacy and Biotechnology in Precision Therapy Development

Aspect	Role of Pharmacy	Role of Biotechnology	Contribution to Healthcare Quality
Drug Development	Formulation optimization and dosage design	Genetic engineering and target identification	Increased drug efficacy
Diagnostic Support	Interpretation of pharmacogenomic tests	Biomarker and molecular diagnostic development	Accurate patient stratification
Clinical Application	Medication therapy management	Production of biologics and gene therapies	Reduced adverse drug reactions
Patient Safety	Monitoring and pharmacovigilance	Molecular safety profiling	Improved treatment safety
Sustainability	Rational drug use	Efficient biotechnological production	Cost-effective healthcare delivery

These findings are consistent with previous international studies reporting that interdisciplinary integration enhances treatment accuracy and patient satisfaction. However, challenges such as high costs, regulatory complexity, and limited professional competency remain barriers to widespread implementation. The implications of these findings underscore the need for policy support, curriculum reform in pharmaceutical education, and sustained investment in biotechnological infrastructure. Although this study is limited to secondary data, it provides a strong conceptual foundation for future empirical and experimental research.

The integration of pharmacy and biotechnology in precision therapy has led to significant advancements in patient care. Biotechnological innovations such as biologics, biosimilars, and gene therapies have expanded the scope of precision therapy by enabling the development of targeted treatments that are specifically designed to address the genetic and molecular characteristics of individual patients. These treatments have demonstrated improved therapeutic efficacy, particularly in oncology and genetic disorders, where traditional treatments often have limited success.

Pharmacogenomics, which enables the identification of genetic markers that influence drug response, has played a crucial role in optimizing the effectiveness of these therapies. The ability to predict how a patient will respond to specific medications has reduced the likelihood of adverse drug reactions and increased the overall success rate of treatments.

Pharmacogenomic testing has been particularly valuable in oncology, where individual genetic variations can determine the success of chemotherapy drugs. By tailoring chemotherapy regimens based on patients' genetic profiles, healthcare providers can ensure that patients receive the most effective treatment while minimizing unnecessary side effects. This has improved patient outcomes, particularly in cancers that have been traditionally difficult to treat, such as breast, lung, and ovarian cancers. Moreover, the integration of pharmacogenomics into clinical practice has also reduced the number of adverse drug reactions, which remain a leading cause of hospital admissions and healthcare costs worldwide. This reduction in adverse effects has not only improved the quality of care but has also made precision therapy more cost-effective in the long run.

The collaboration between pharmacists and biotechnologists has further enhanced the clinical decision-making process by facilitating the translation of complex biotechnological data, such as genetic profiles and biomarker results, into actionable therapeutic recommendations. Pharmacists, with their expertise in drug interactions, pharmacokinetics, and pharmacodynamics, have been pivotal in helping clinicians interpret these molecular-level insights and adjust treatment plans accordingly. This partnership has ensured that the latest advancements in biotechnology are seamlessly integrated into patient care, providing a more personalized and effective treatment approach. In clinical settings, this collaboration has been shown to increase patient satisfaction by providing more tailored treatment plans that align with individual needs.

Despite these advancements, challenges remain in the widespread implementation of precision therapy. One of the key barriers identified in this study is the lack of interdisciplinary collaboration between pharmacy and biotechnology professionals, particularly in developing healthcare systems. The fragmentation of healthcare services and the limited access to advanced biotechnological tools have hindered the full integration of precision medicine in many regions. In addition, there is a shortage of professionals with the specialized knowledge required to implement and manage precision therapies, which has slowed the adoption of these innovations. Addressing these gaps requires significant investment in both education and healthcare infrastructure to ensure that professionals are equipped with the necessary skills to utilize these advanced therapies effectively.

Another significant challenge identified in this study is the high cost of biotechnological treatments, which often limits access to precision therapy for underserved populations. The high production costs of biologics, gene therapies, and other biotechnological products, combined with the complexity of regulatory approval processes, make these therapies expensive to manufacture and distribute. While the long-term benefits of precision therapy, such as reduced adverse drug reactions and improved treatment outcomes, may offset these initial costs, the affordability of these treatments remains a major concern. Public and private stakeholders must work together to reduce the financial burden of precision therapies, making them accessible to a broader range of patients.

The findings also highlight the need for stronger policy support to facilitate the integration of biotechnology into pharmaceutical practices. Regulatory frameworks that are more flexible and adaptive to the evolving field of biotechnology are crucial for ensuring that new treatments can be rapidly developed and made available to patients. Additionally, there is a need for more comprehensive reimbursement policies that support the cost of precision therapies, which are often

not covered by traditional insurance models. These policies should be designed to reflect the long-term cost savings and improved health outcomes that precision therapies offer.

Finally, this study emphasizes the importance of enhancing the curriculum in pharmaceutical education to include more focus on biotechnology and precision medicine. As precision therapy becomes an integral part of modern healthcare, it is essential that future pharmacists are trained to understand the principles of biotechnology and how it can be applied to patient care. This will help pharmacists better support interdisciplinary collaboration, interpret complex genetic and molecular data, and contribute to the successful implementation of precision medicine in clinical practice. The integration of biotechnology into pharmaceutical education will ensure that the next generation of pharmacists is well-prepared to meet the challenges and opportunities of the rapidly evolving healthcare landscape.

CONCLUSION

The synergy between pharmacy and biotechnology is essential for the development of precision therapy and the improvement of healthcare service quality. By integrating biotechnological innovations into pharmaceutical practice, healthcare systems can deliver more effective, safe, and personalized treatment. This study highlights the strategic importance of interdisciplinary collaboration in achieving sustainable, patient-centered healthcare.

DECLARATION OF AI AND AI ASSISTED TECHNOLOGIES IN THE WRITING PROCESS

During the preparation of this work, the author(s) used ChatGPT (OpenAI) to assist with language refinement, improving clarity and coherence, and supporting the organization of the manuscript. After using this tool, the author(s) carefully reviewed, verified, and edited the generated content as necessary and take full responsibility for the accuracy, integrity, originality, and final content of the publication.

ACKNOWLEDGEMENT

This is a short text to acknowledge the contributions of specific colleagues, institutions, or agencies that aided the efforts of the authors.

AUTHORS' CONTRIBUTION

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.

Author 2: Conceptualization; Data curation; Investigation.

Author 3: Data curation; Investigation.

DECLARATION OF COMPETING INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

- Leelakrishna Reddy, S. A. (2023). Transforming healthcare with the synergy of biotechnology and information technology. *AIMS Bioengineering*, Volume 10,(4).
<https://doi.org/10.3934/bioeng.2023025>
- Maesaroh, S. A. (2025). Kimia Medisinal dan Perannya Dalam Pengembangan Terapi Personalisasi. *Madani: Jurnal Ilmiah Multidisiplin*, Volume 3,.
<https://doi.org/https://doi.org/10.5281/zenodo.15187886>

- Pawar, D. B., Rani, D. F., Sarkar, A., H, G., & Lakra, J. (2025). The Role Of Pharmacists In Enhancing Rational Drug Use: A Cross-Sectional Study Across Healthcare Settings. *Journal of Population Therapeutics and Clinical Pharmacology*, Vol. 32 No. <https://doi.org/https://doi.org/10.53555/t65vaq57>
- Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. *Journal of Business Research*, Volume 104. <https://doi.org/https://doi.org/10.1016/j.jbusres.2019.07.039>
- Williams, J. (2023). Biomedical Applications Transforming Healthcare through Breakthroughs in Diagnosis, Treatment and Patient Care. *Journal of Biomedical Engineering and Medical Devices*, Volume 8,(2). <https://www.longdom.org/biomedical-engineering-medical-devices.html>
- Abbas, S. (2022). Climate change and major crop production: Evidence from Pakistan. *Environmental Science and Pollution Research*, 29(4), 5406–5414. <https://doi.org/10.1007/s11356-021-16041-4>
- Adhikari, L. (2022). Cold stress in plants: Strategies to improve cold tolerance in forage species. *Plant Stress*, 4(Query date: 2026-04-06 00:37:38). <https://doi.org/10.1016/j.stress.2022.100081>
- Bender, R. (2022). Corrosion challenges towards a sustainable society. *Materials and Corrosion*, 73(11), 1730–1751. <https://doi.org/10.1002/maco.202213140>
- Berg, C. D. (2023). Air Pollution and Lung Cancer: A Review by International Association for the Study of Lung Cancer Early Detection and Screening Committee. *Journal of Thoracic Oncology*, 18(10), 1277–1289. <https://doi.org/10.1016/j.jtho.2023.05.024>
- Bryan, E. (2024). Addressing gender inequalities and strengthening women’s agency to create more climate-resilient and sustainable food systems. *Global Food Security*, 40(Query date: 2026-04-06 00:37:38). <https://doi.org/10.1016/j.gfs.2023.100731>
- Büyüközkan, G. (2022). A review of urban resilience literature. *Sustainable Cities and Society*, 77(Query date: 2026-04-06 00:37:38). <https://doi.org/10.1016/j.scs.2021.103579>
- Calliari, E. (2022). Building climate resilience through nature-based solutions in Europe: A review of enabling knowledge, finance and governance frameworks. *Climate Risk Management*, 37(Query date: 2026-04-06 00:37:38). <https://doi.org/10.1016/j.crm.2022.100450>
- Campbell-Lendrum, D. (2023). Climate change and health: Three grand challenges. *Nature Medicine*, 29(7), 1631–1638. <https://doi.org/10.1038/s41591-023-02438-w>
- Carr, T. W. (2022). Climate change impacts and adaptation strategies for crops in West Africa: A systematic review. *Environmental Research Letters*, 17(5). <https://doi.org/10.1088/1748-9326/ac61c8>
- Chen, L. (2023). Artificial intelligence-based solutions for climate change: A review. *Environmental Chemistry Letters*, 21(5), 2525–2557. <https://doi.org/10.1007/s10311-023-01617-y>
- Cooper, M. (2023). Breeding crops for drought-Affected environments and improved climate resilience. *Plant Cell*, 35(1), 162–186. <https://doi.org/10.1093/plcell/koac321>
- Dharmarathne, G. (2024). Adapting cities to the surge: A comprehensive review of climate-induced urban flooding. *Results in Engineering*, 22(Query date: 2026-04-06 00:37:38). <https://doi.org/10.1016/j.rineng.2024.102123>
- Fan, J. L. (2023). A net-zero emissions strategy for China’s power sector using carbon-capture utilization and storage. *Nature Communications*, 14(1). <https://doi.org/10.1038/s41467-023-41548-4>

- Hanson, E. (2025). Carbon capture, utilization, and storage (CCUS) technologies: Evaluating the effectiveness of advanced CCUS solutions for reducing CO₂ emissions. *Results in Surfaces and Interfaces*, 18(Query date: 2026-04-06 00:37:38). <https://doi.org/10.1016/j.rsurfi.2024.100381>
- Iungman, T. (2023). Cooling cities through urban green infrastructure: A health impact assessment of European cities. *Lancet*, 401(10376), 577–589. [https://doi.org/10.1016/S0140-6736\(22\)02585-5](https://doi.org/10.1016/S0140-6736(22)02585-5)
- Jain, H. (2023). AI-enabled strategies for climate change adaptation: Protecting communities, infrastructure, and businesses from the impacts of climate change. *Computational Urban Science*, 3(1). <https://doi.org/10.1007/s43762-023-00100-2>
- Jat, M. L. (2022). Carbon sequestration potential, challenges, and strategies towards climate action in smallholder agricultural systems of South Asia. *Crop and Environment*, 1(1), 86–101. <https://doi.org/10.1016/j.crope.2022.03.005>
- Kabir, E. (2023). Biochar as a tool for the improvement of soil and environment. *Frontiers in Environmental Science*, 11(Query date: 2026-04-06 00:37:38). <https://doi.org/10.3389/fenvs.2023.1324533>
- Kamyab, H. (2024). Carbon dynamics in agricultural greenhouse gas emissions and removals: A comprehensive review. *Carbon Letters*, 34(1), 265–289. <https://doi.org/10.1007/s42823-023-00647-4>
- Khan, M. H. U. (2022). Applications of Artificial Intelligence in Climate-Resilient Smart-Crop Breeding. *International Journal of Molecular Sciences*, 23(19). <https://doi.org/10.3390/ijms231911156>
- Lazaroiu, A. C. (2023). A Comprehensive Overview of Photovoltaic Technologies and Their Efficiency for Climate Neutrality. *Sustainability Switzerland*, 15(23). <https://doi.org/10.3390/su152316297>
- Mandal, S. (2023). Biostimulants and environmental stress mitigation in crops: A novel and emerging approach for agricultural sustainability under climate change. *Environmental Research*, 233(Query date: 2026-04-06 00:37:38). <https://doi.org/10.1016/j.envres.2023.116357>
- McPhearson, T. (2022). A social-ecological-technological systems framework for urban ecosystem services. *One Earth*, 5(5), 505–518. <https://doi.org/10.1016/j.oneear.2022.04.007>
- Mekonnen, T. W. (2022). Breeding of Vegetable Cowpea for Nutrition and Climate Resilience in Sub-Saharan Africa: Progress, Opportunities, and Challenges. *Plants*, 11(12). <https://doi.org/10.3390/plants11121583>
- Mohammed, S. (2022). Assessing the impacts of agricultural drought (SPI/SPEI) on maize and wheat yields across Hungary. *Scientific Reports*, 12(1). <https://doi.org/10.1038/s41598-022-12799-w>
- Nerkar, G. (2022). Advances in Crop Breeding Through Precision Genome Editing. *Frontiers in Genetics*, 13(Query date: 2026-04-06 00:37:38). <https://doi.org/10.3389/fgene.2022.880195>
- Orsetti, E. (2022). Building Resilient Cities: Climate Change and Health Interlinkages in the Planning of Public Spaces. *International Journal of Environmental Research and Public Health*, 19(3). <https://doi.org/10.3390/ijerph19031355>
- Patel, L. (2022). Climate Change and Extreme Heat Events: How Health Systems Should Prepare. *Nejm Catalyst Innovations in Care Delivery*, 3(7). <https://doi.org/10.1056/CAT.21.0454>
- Raza, A. (2023). Assessment of proline function in higher plants under extreme temperatures. *Plant Biology*, 25(3), 379–395. <https://doi.org/10.1111/plb.13510>

- Scott, D. (2022). A review of research into tourism and climate change—Launching the annals of tourism research curated collection on tourism and climate change. *Annals of Tourism Research*, 95(Query date: 2026-04-06 00:37:38). <https://doi.org/10.1016/j.annals.2022.103409>
- Sousa, R. d. (2024). Challenges and Solutions for Sustainable Food Systems: The Potential of Home Hydroponics. *Sustainability Switzerland*, 16(2). <https://doi.org/10.3390/su16020817>
- Srivastava, A. (2023). Assessing the Potential of AI–ML in Urban Climate Change Adaptation and Sustainable Development. *Sustainability Switzerland*, 15(23). <https://doi.org/10.3390/su152316461>
- Straffellini, E. (2023). Climate change-induced aridity is affecting agriculture in Northeast Italy. *Agricultural Systems*, 208(Query date: 2026-04-06 00:37:38). <https://doi.org/10.1016/j.agsy.2023.103647>
- Syed, A. (2022). Climate Impacts on the agricultural sector of Pakistan: Risks and solutions. *Environmental Challenges*, 6(Query date: 2026-04-06 00:37:38). <https://doi.org/10.1016/j.envc.2021.100433>
- Wang, L. (2022). A review of the flood management: From flood control to flood resilience. *Heliyon*, 8(11). <https://doi.org/10.1016/j.heliyon.2022.e11763>
- Woodruff, S. C. (2022). Adaptation to Resilience Planning: Alternative Pathways to Prepare for Climate Change. *Journal of Planning Education and Research*, 42(1), 64–75. <https://doi.org/10.1177/0739456X18801057>
- Xiong, W. (2022). Climate change challenges plant breeding. *Current Opinion in Plant Biology*, 70(Query date: 2026-04-06 00:37:38). <https://doi.org/10.1016/j.pbi.2022.102308>
- Yang, Y. (2024). Climate change exacerbates the environmental impacts of agriculture. *Science*, 385(6713). <https://doi.org/10.1126/science.adn3747>
- Zhou, Y. (2023). Climate change adaptation with energy resilience in energy districts—A state-of-the-art review. *Energy and Buildings*, 279(Query date: 2026-04-06 00:37:38). <https://doi.org/10.1016/j.enbuild.2022.112649>

Copyright Holder :

© Rifa Andriana et.al (2026).

First Publication Right :

© Journal of Advanced Pharmaceutical Research Sciences and Sustainability (JAPRSS)

This article is under:

